We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.225 | 5.81% | 4.10 | 4.05 | 4.15 | 4.275 | 3.825 | 3.88 | 29,115,559 | 16:25:52 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0095 | -4.32 | 21.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2024 16:26 | Worried if nice is not approved will this crash | professoraim | |
26/7/2024 16:24 | Ahhhh bless BIG DADDY I'm still waiting for your reply! | z1co | |
26/7/2024 16:22 | Will we see some large buys after the close? Seems like the MM’s have been controlling this all day. | daddy warbucks | |
26/7/2024 16:22 | MM's need all they can get for the expected surge in volume next week | z1co | |
26/7/2024 16:21 | NT to buy for even 25,000 @ 4.10p | z1co | |
26/7/2024 16:14 | Well zico I'm fully loaded now for next week so let the games begin 8am Monday morning | diggit180 | |
26/7/2024 16:09 | MM's playing with traders they drop the offer to 4.10p but only allowing small buys. No quote for 100,000 | z1co | |
26/7/2024 16:00 | to get a sense of the direction of travel GDR is on - recent RNS's 20/12/23 MT-RNR1 initial oversears orders 24/4/24 MT-RNR1 US clinical trial agreement made 21/5/24 CYP2C19 - test performance milestone achieved 24/5/24 MT-RNR1 initial UK orders 15/7/24 CYP2c19 - US FDA breakthrough status achieved | chatchat | |
26/7/2024 15:52 | I see Batti the BLATANT LIAR is still posting LIES | z1co | |
26/7/2024 15:19 | Batiatus From your post 341 where I highlighted that £6m funding is already in the GDR bank account. " Chatchat, good post. At least some information about GDR and their plans". | chatchat | |
26/7/2024 15:19 | Afternoon all. Well rested and ready for a long weekend away from the boards. Please all try to take time out and relax whilst the markets are closed, nothing can be done about positions anyway. | premium beeks | |
26/7/2024 15:13 | However always appreciate people's charts. Whilst not written in stone always interesting. | hazl | |
26/7/2024 15:13 | Trading error is buying in without full confirmation of NICE and funding strategy | batiatus | |
26/7/2024 15:12 | GTo be honest nobody makes us press the button or decide not to. We have to be responsible for our own decisions. | hazl | |
26/7/2024 14:57 | Soci , That's a NICE CHART saying 6p i believe Approval confirmation i expect a lot higher | z1co | |
26/7/2024 14:52 | Just my latest short term view: Staying off the forums for a while. Made a significant trading error yesterday as a result of Beeks' mind-games. | socionomics | |
26/7/2024 14:50 | This BLATANT LIAR has posted that the company does NOT have any products approved when in fact MT-RNR1 ID Kit was approved last year and is being sold to hospitals. How could anyone trust such a BLATANT LIAR , his latest post above is of no real substance. On yer bike | z1co | |
26/7/2024 14:38 | MM's will take the price sharply lower in the last 30 minutes of trading. Quite a few trigger happy traders were very happy to be sucked in. | batiatus | |
26/7/2024 14:29 | MM's will take the price sharply higher in the last 30 minutes of trading. Quite a few trigger happy traders gave their shares away far too cheaply. | z1co | |
26/7/2024 14:16 | The publication will be on 31/07/2024 as per NICE web page. Next Wednesday and NOT on Monday | z1co | |
26/7/2024 14:14 | 31st It is. | hazl | |
26/7/2024 14:06 | The last paragraph is of significant importance if NICE were not going to approve CYP2C19 ID Test then why would they say quote: "NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance." | z1co |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions